| Beloranib | |
|---|---|
|
[(3R,6R,7S,8S)-7-methoxy-8-[(2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-2-oxaspiro[2.5]octan-6-yl] (E)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate |
|
|
Other names
CKD-732; ZGN-433 |
|
| Identifiers | |
| CAS number | 251111-30-5 , 529511-79-3 (hemioxalate) |
| PubChem | 6918502 |
| ChemSpider | 26286923 |
| UNII | FI471K8BU6 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C29H41NO6 |
| Molar mass | 499.64 g mol−1 |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Beloranib is an experimental drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and is currently being developed by Zafgen.[1]
Beloranib, an analog of the natural chemical compound fumagillin, is an inhibitor of the enzyme METAP2.[2] It was originally designed as angiogenesis inhibitor for the treatment of cancer.[3] However, once the potential anti-obesity effects of METAP2 inhibition became apparent, the clinical development began to focus on these effects and beloranib has shown positive results in preliminary clinical trials for this indication.[4][5]